Literature DB >> 7962300

Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion.

G Mastorakos1, J S Weber, M A Magiakou, H Gunn, G P Chrousos.   

Abstract

We recently demonstrated that sc administered interleukin-6 (IL-6) strongly stimulates the human hypothalamic-pituitary-adrenal (HPA) axis, with mild toxicity and no hypotensive effects. In this study, we evaluated the response of the human HPA axis to escalating iv doses of recombinant IL-6 in six patients with cancer and good performance status who received daily, every 8 h, three equal doses of 0.3-30 micrograms/kg IL-6. The plasma levels of IL-6 assayed by a specific enzyme-linked immunosorbent assay during the 4 h following the first IL-6 injection were elevated for 2-4 h, proportionally to the amount of injected IL-6. Administration of the cytokine was followed by marked elevations of plasma ACTH (53.0-98.6 pmol/L) and cortisol (824.9-1729.9 nmol/L) independently of the IL-6 dose administered, suggesting that the doses employed were at the top of the dose-response curve for these hormones. Interestingly, plasma arginine vasopressin (AVP) levels were also elevated during the 2 h after IL-6 injection in all patients who received a dose of 3 micrograms/kg or more, suggesting that IL-6 activated the magnocellular AVP-secreting neurons and that it might be involved in the syndrome of inappropriate AVP secretion. Cortisol elevations with peaks similar to those observed after the first injection of IL-6 were also detected in plasma sampled every 2 h after the second and third injections, suggesting that there was no rapid tachyphylaxis in response to IL-6 administration. Plasma IL-1 beta and tumor necrosis factor-alpha concentrations, assayed by specific enzyme-linked immunosorbent assays during the 4 h after the first IL-6 injection, were either within the normal range or undetectable, confirming in vitro observations that IL-6 does not stimulate IL-1 beta or tumor necrosis factor-alpha secretion and suggesting that it exerts its effect on the HPA axis and AVP secretion independently of them. We conclude that IL-6 is a potent stimulator of the human HPA axis and a secretagogue of magnocellular AVP secretion, which might be employed as a challenge test of the axis and the magnocellular AVP neuron.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962300     DOI: 10.1210/jcem.79.4.7962300

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  64 in total

Review 1.  Obesity and adipokines: effects on sympathetic overactivity.

Authors:  Michael M Smith; Christopher T Minson
Journal:  J Physiol       Date:  2012-02-20       Impact factor: 5.182

2.  Kawasaki disease and hyponatremia.

Authors:  Jae Il Shin; Ji Hong Kim; Jae Seung Lee; Dong Soo Kim; Jae Young Choi; Jun Hui Sul
Journal:  Pediatr Nephrol       Date:  2006-08-08       Impact factor: 3.714

3.  High Fever induced by dexamethasone withdrawal.

Authors:  L Margolin; R Bakst-Sisser; M Segal; J Nissinoff; M Thomas
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

4.  Exercise-associated hyponatremia.

Authors:  William G Schucany
Journal:  Proc (Bayl Univ Med Cent)       Date:  2007-10

5.  Exercise-associated hyponatremia: the influence of pre-exercise carbohydrate status combined with high volume fluid intake on sodium concentrations and fluid balance.

Authors:  Kimberly A Hubing; John T Bassett; Laura R Quigg; Melody D Phillips; James J Barbee; Joel B Mitchell
Journal:  Eur J Appl Physiol       Date:  2010-11-03       Impact factor: 3.078

6.  Organization and Integration of the Endocrine System.

Authors:  George P Chrousos
Journal:  Sleep Med Clin       Date:  2007-06

7.  Persistent endocrine stress response in patients undergoing cardiac surgery.

Authors:  A Roth-Isigkeit; J Brechmann; L Dibbelt; H H Sievers; W Raasch; P Schmucker
Journal:  J Endocrinol Invest       Date:  1998-01       Impact factor: 4.256

Review 8.  Management of vasodilatory shock: defining the role of arginine vasopressin.

Authors:  Martin W Dunser; Volker Wenzel; Andreas J Mayr; Walter R Hasibeder
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Detrimental effects of chronic hypothalamic-pituitary-adrenal axis activation. From obesity to memory deficits.

Authors:  J Raber
Journal:  Mol Neurobiol       Date:  1998-08       Impact factor: 5.590

Review 10.  The emerging role of peripheral corticotropin-releasing hormone (CRH).

Authors:  I Ilias; G Mastorakos
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.